2008/980/EC: Commission Decision of 5 December 2008 appointing members and alternates of the Committee for Advanced Therapies to represent clinicians and patients associations (Text with EEA relevance)
Date: 2008-12-05
Institutions: European Commission
Subjects: EU research policy, European Medicines Agency, appointment of staff, medical research, medicinal product, pharmaceutical legislation

31.12.2008

EN

Official Journal of the European Union

L 352/31

COMMISSION

COMMISSION DECISION

of 5 December 2008

appointing members and alternates of

the Committee for Advanced Therapies to represent

clinicians and patients associations

(Text with EEA relevance)

(2008/980/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

(5)

The members and alternates of
the Committee for
Advanced Therapies should be appointed for a period
of three years, starting on the date of application of
Regulation (EC) No 1394/2007,

HAS DECIDED AS FOLLOWS:

Article 1

The following are hereby appointed members and alternates of
the Committee for Advanced Therapies to represent clinicians
for a term of three years, from 30 December 2008:

— Dietger Niederwieser

(Member)

and

Per

Ljungman

(Alternate),

— George Dickson (Member) and Thierry VandenDriessche

(Alternate).

Article 2

The following are hereby appointed members and alternates of
the Committee for Advanced Therapies to represent patients
associations for a term of three years, from 30 December 2008:

— Fabrizia Bignami
(Alternate),

(Member) and Michele Lipucci di Paola

— Alastair Kent (Member) and Nicholas Meade (Alternate).

Done at Brussels, 5 December 2008.

For the Commission

Günter VERHEUGEN
Vice-President

Having regard to the Treaty
Community,

establishing the European

the
Having regard to Regulation (EC) No 1394/2007 of
European Parliament and of
the Council of 13 November
2007 on advanced therapy medicinal products and amending
Directive 2001/83/EC and Regulation (EC) No 726/2004 (1),
and in particular Article 21(1) thereof,

Whereas:

(1)

(2)

(3)

(4)

Regulation (EC) No 1394/2007 lays down specific rules
concerning the authorisation, supervision and pharma­
covigilance of advanced therapy medicinal products.
Article 20 of
a
Committee for Advanced Therapies shall be established
within the European Medicines Agency.

that Regulation lays down that

Subparagraph (c) of Article 21(1) of Regulation (EC) No
1394/2007 lays down that the Committee for Advanced
Therapies shall include two members and two alternates
appointed by the Commission, on the basis of a public
call for expressions of interest and after consulting the
European Parliament, in order to represent clinicians.

Subparagraph (d) of Article 21(1) of Regulation (EC) No
1394/2007 lays down that the Committee for Advanced
Therapies shall include two members and two alternates
appointed by the Commission, on the basis of a public
call for expressions of interest and after consulting the
European Parliament, in order to represent patients asso­
ciations.

In accordance with Article 21(1) of Regulation (EC) No
1394/2007, a public call for expressions of interest has
been undertaken by the Commission. The European
Parliament has also been consulted on the results of
the evaluation of the applications received.

(1) OJ L 324, 10.12.2007, p. 121.